Fuller & Thaler Asset Management, Inc. Acadia Pharmaceuticals Inc Transaction History

Fuller & Thaler Asset Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$17.79 - $30.86 $11.4 Million - $19.8 Million	-641,112 Reduced 99.99%	73 $1,000
Q4 2023 Feb 13, 2024	BUY	$20.78 - $31.77 $13.3 Million - $20.4 Million	641,185 New	641,185 $20.1 Million
Q4 2018 Feb 14, 2019	SELL	$14.32 - $22.92 $6.26 Million - $10 Million	-437,255 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$13.03 - $21.81 $5.7 Million - $9.54 Million	437,255 New	437,255 $9.08 Million

280

156M

901K

297K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.75B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Fuller & Thaler Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Fuller & Thaler Asset Management, Inc. with notifications on news.